Sara Isoldi

Dr. Sara Isoldi


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
CCClaudia Carissimi
Claudia Carissimi
ILIlaria Laudadio
Ilaria Laudadio
FPFrancesca Palone
Francesca Palone
VFValerio Fulci
Valerio Fulci
VCVincenzo Cesi
Vincenzo Cesi
LSLaura Stronati
Laura Stronati

7 November 2013 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
Giovanni Di NardoGiovanni Di Nardo
Giovanni Di Nardo
GBG. Barbara
G. Barbara
SCSalvatore Cucchiara
Salvatore Cucchiara
CCC. Cremon
C. Cremon
RSR. J. Shulman
R. J. Shulman
LSLaura Stronati
Laura Stronati

1 November 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
SISara Isoldi
Sara Isoldi
DBDalia Belsha
Dalia Belsha
IYIntan Yeop
Intan Yeop
AUAliye Uc
Aliye Uc
NZNoam Zevit
Noam Zevit
MTMike Thomson
Mike Thomson

11 February 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
SISara Isoldi
Sara Isoldi
SMSaverio Mallardo
Saverio Mallardo
AMAlessia Marcellino
Alessia Marcellino
SBSilvia Bloise
Silvia Bloise
ADAnna Dilillo
Anna Dilillo
RLRiccardo Lubrano
Riccardo Lubrano
Objectives: To perform a comprehensive clinic, laboratory, and instrumental evaluation of children affected by coronavirus disease (COVID‐19).Methods: Children with a positive result of nasopharyngeal swab for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) underwent laboratory tests, anal and conjunctival swab, electrocardiography, lung, abdomen, and cardiac ultrasound. Twenty‐four‐hour ambulatory blood pressure monitoring was performed if abnormal basal blood pressure. Patients were followed‐up for 6 months.Results: Three hundred and sixteen children were evaluated; 15 were finally included. Confirmed family member SARS‐CoV‐2 infection was present in all. Twenty‐seven percent were asymptomatic. Anal and conjunctival swabs tests resulted negative in all. Patients with lower body mass index (BMI) presented significantly higher viral loads. Main laboratory abnormalities were: lactate dehydrogenase increasing (73%), low vitamin D levels (87%), hematuria (33%), proteinuria (26%), renal hyperfiltration (33%), and hypofiltration (13%). Two of the patients with hyperfiltration exhibited high blood pressure levels at diagnosis, and persistence of prehypertension at 6‐month follow‐up. No abnormalities were seen at ultrasound, excepting for one patient who exhibited B‐lines at lung sonography. Immunoglobulin G seroconversion was observed in all at 1‐month.Conclusions: Our study confirm that intra‐family transmission is important. The significant higher viral loads recorded among patients with lower BMI, together with low vitamin D levels, support the impact of nutritional status on immune system. Renal involvement is frequent even among children with mild COVID‐19, therefore prompt evaluation and identification of patients with reduced renal function reserve would allow a better stratification and management of patients. Seroconversion occurs also in asymptomatic children, with no differences in antibodies titer according to age, sex and clinical manifestations.

26 April 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LSLaura Stronati
Laura Stronati
FPFrancesca Palone
Francesca Palone
ANAnna Negroni
Anna Negroni
ECEleonora Colantoni
Eleonora Colantoni
AMAnna Barbara Mancuso
Anna Barbara Mancuso
RVRoberta Vitali
Roberta Vitali
Gut mucosal healing (MH) is considered a key therapeutic target and prognostic parameter in the management of inflammatory bowel disease (IBD). The dipotassium glycyrrhizate (DPG), a salt of the glycoconjugated triterpene glycyrrhizin, has been shown to inhibit the High Mobility Group Box 1 (HMGB1) protein, an allarmin strongly implicated in the pathogenesis of most inflammatory and auto-immune disorders. Here we discuss new insights on how DPG acts on MH comparing the acute phase and the recovery phase from experimental colitis in mice. We found that DPG strongly accelerates MH by differently regulating pro-inflammatory (CXCL1, CXCL3, CXCL5, PTGS2, IL-1β, IL-6, CCL12, CCL7) and wound healing (COL3A1, MMP9, VTN, PLAUR, SERPINE, CSF3, FGF2, FGF7, PLAT, TIMP1) genes as observed only during the recovery phase of colitis. Relevant issue is the identification of extracellular matrix (ECM) remodeling genes, VTN, and PLAUR, as crucial genes to achieve MH during DPG treatment. Furthermore, a noticeable recovery of intestinal epithelial barrier structural organization, wound repair ability, and functionality is observed in two human colorectal adenocarcinoma cell lines exposed to DPG during inflammation. Thus, our study identifies DPG as a potent tool for controlling intestinal inflammation and improving MH.

22 May 2021 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SBSilvia Bloise
Silvia Bloise
AMAlessia Marcellino
Alessia Marcellino
ATAlessia Testa
Alessia Testa
ADAnna Dilillo
Anna Dilillo
SMSaverio Mallardo
Saverio Mallardo
RLRiccardo Lubrano
Riccardo Lubrano
Since the outbreak of SARS-CoV-2 among the population has occurred quite recently, there is a lack of evidence on the long-term duration of antibody response, especially in children. It is therefore crucial to clarify this aspect, considering its implications in the development of successful surveillance strategies, therapies, and vaccinations. The aim of this study was to assess the antibody response in a children group after SARS-CoV-2 infection, and to compare it with that of their parents affected by SARS-CoV-2 infection. We enrolled 12 children and their parents, both groups being affected by COVID-19 in April 2020. In the children’s group, we collected real-time RT-PCR cycle threshold (Ct) values and gene characterization of first nasal-throat swab at the time of diagnosis (T0); 30 days after the diagnosis (T30), we performed blood tests to detect anti-SARS-CoV-2 IgM and IgG. Finally, 180 days after the diagnosis (T180), we measured anti-SARS-CoV-2 IgG in both children and parents. In children, antibody levels declined significantly at 180 days (T180) after first measurement (T30). There were no significant differences in IgG level related to age, sex, and clinical manifestations. We found a significant correlation between IgG titers at T30 and Ct value of gene N. Children showed a lower level of antibodies against SARS-CoV-2 at T180 compared to their parents.Conclusion: Antibody responses in children waned 180 days after SARS-CoV-2 infection, and at the same time, their parents showed a different antibody response to the virus. These results highlight that serological tests should be used with caution in surveillance strategies among the general population. What is known:• Currently is not known how long antibody response will be maintained or if it protects from reinfection.• Recent reports in adults suggest that antibodies to SARS-CoV-2 declined several months after infection, but data are missing in pediatric age. What is new:• We showed that antibody responses to SARS-CoV-2 wane several months after infection also in children with quantitative differences in antibody levels between children and adults.• In this context, serological tests should be used with caution in surveillance strategies.